Fortrea Holdings (FTRE) EBT (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly EBT came in at -$1.2 million in Q2 2026, up 99.68% YoY from -$600972.7 in Q2 2025, and up 90.24% on a QoQ basis from -$12.3 million in Q1 2026.
Analysis
Fortrea Holdings (FTRE) EBT (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of EBT data on file, last reported at -$1.2 million in Q2 2026.
- Quarterly EBT rose 99.68% year-over-year to -$1.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$77.8 million (up 92.44% YoY) and the FY2025 annual result came in at -$983.0 million, down 257.45% from the prior year.
- EBT rose to -$1.2 million in Q2 2026, from -$12.3 million in the prior quarter.
- In the past five years, EBT ranged from a high of $83.6 million in Q2 2022 to a low of -$548.0 million in Q1 2025.
- A 5-year average of -$67.8 million and a median of -$28.7 million in 2025 frame the typical range for EBT.
- Annual changes were most pronounced in 2024 — EBT slumped 896.84% — and 2026, when it soared 99.68%.
- Tracing FTRE's EBT over 5 years: stood at -$8.3 million in 2022, then sank by 559.04% to -$54.7 million in 2023, then slumped by 36.93% to -$74.9 million in 2024, then jumped by 52.47% to -$35.6 million in 2025, then soared by 96.63% to -$1.2 million in 2026.
- The last three EBT figures came in at -$1.2 million (Q2 2026), -$12.3 million (Q1 2026), and -$35.6 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn | 542.00 Mn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn | -767.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn | 312.46 Mn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn | 177.81 Mn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Fortrea Holdings | 1.73 Bn | 1.56 Bn | 139.20 Mn | -1.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.20 Mn |
| Mar 31, 2026 | -12.30 Mn |
| Dec 31, 2025 | -35.60 Mn |
| Sep 30, 2025 | -28.70 Mn |
| Jun 30, 2025 | -370.70 Mn |
| Mar 31, 2025 | -548.00 Mn |
| Dec 31, 2024 | -74.90 Mn |
| Sep 30, 2024 | -35.80 Mn |
| Jun 30, 2024 | -88.60 Mn |
| Mar 31, 2024 | -75.70 Mn |
| Dec 31, 2023 | -54.70 Mn |
| Sep 30, 2023 | -21.90 Mn |
| Jun 30, 2023 | 36.60 Mn |
| Mar 31, 2023 | 9.50 Mn |
| Dec 31, 2022 | -8.30 Mn |
| Sep 30, 2022 | 74.20 Mn |
| Jun 30, 2022 | 83.60 Mn |